Analysis of Selenium Levels in Osteosarcoma Patients and the Effects of Se-Methylselenocysteine on Osteosarcoma Cells In Vitro

REFERENCES

• Chen JT, Fong YC, Li TM, Liu JF, Hsu CW, et al.: DDTD, an isoflavone derivative, induces cell apoptosis through the reactive oxygen species/apoptosis signal-regulating kinase 1 pathway in human osteosarcoma cells. Eur J Pharmaco 597, 19–26, 2008.
   PubMed Web of Science ®Google Scholar
• Lee JA, Kim MS, Kim DH, Lim JS, Yoo JY, et al.: Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 50, 195–200, 2008.
   PubMed Web of Science ®Google Scholar
• Ip C, Thomson HJ, and Ganther HE: Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland. Cancer Epidemiol Biomarkers Prev 9, 49–54, 2000.
   PubMed Web of Science ®Google Scholar
• Gazi MH, Gong A, Donkena KV, and Young CY: Sodium selenite inhibits interleukin-6-mediated and rogen receptor activation in prostate cancer cells via upregulation of c-Jun. Clin Chim Acta 380, 145–150, 2007.
   PubMed Web of Science ®Google Scholar
• Yamanoshita O, Ichihara S, Hama H, Ichihara G, Chiba M, et al.: Chemopreventive effect of selenium-enriched Japanese radish sprout against breast cancer induced by 7,12-dimethylbenz-[a]anthracene in rats. Tohoku J Exp Med 212, 191–198, 2007.
   PubMed Web of Science ®Google Scholar
• Ip C, Thompson HJ, Zhu Z, and Ganther HE: In vitro and in vivo studies of methylselenic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60, 2882–2886, 2000.
   PubMed Web of Science ®Google Scholar
• Christensen MJ: Selenium and prostate cancer prevention: what next—if anything? Cancer Prev Res (Phila) 7, 781–785, 2014.
   PubMed Web of Science ®Google Scholar
• Richie JP Jr, Das A, Calcagnotto AM, Sinha R, Neidig W, et al.: Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial. Cancer Prev Res (Phila) 7, 796–804, 2014.
   PubMed Web of Science ®Google Scholar
• Lee TJ, Kim YH, Min do S, Park JW, and Kwon TK: Se-methylselenocysteine enhances PMA-mediated CD11c expression via phospholipase D1 activation in U937 cells. Immunology 211, 369–376, 2006.
   Google Scholar
• Cai XJ, Block E, Uden PC, Zhang X, Quimby BD, and Sullivan JJ: Allium chemistry: identification of selenoamino acids in ordinary and selenium-enriched garlic, onion, and broccoli using gas chromatography with atomic emission detection. J Agric Food Chem 43, 1754–1757, 1995.
   Web of Science ®Google Scholar
• Medina D, Thompson H, Ganther H, and Ip C: Se-Methylselenocysteine: A new compound for chemoprevention of breast cancer. Nutr Cancer 40, 12–17, 2001.
   PubMed Web of Science ®Google Scholar
• Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, et al.: Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat 118, 33–43, 2009.
   PubMed Web of Science ®Google Scholar
• Unni E, Kittrell FS, Singh U, and Sinha R: Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res 6, R586–R592, 2004.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Turowski SG, San Martin ID, Rajput A, Rustum YM, et al.: Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer Res 31, 387–393, 2011.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Toth K, Sen A, Seshadri M, Cao S, et al.: Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clin Colorectal Cancer 8, 155–162, 2009.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A: Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv 8, 746–763, 2011.
   Web of Science ®Google Scholar
• Yin MB, Li ZR, Toth K, Cao S, Durrani FA, et al.: Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis. Oncogene 25, 2509–2519, 2006.
   PubMed Web of Science ®Google Scholar
• Hiraoka S, Komiya S, Hamada T, Zenmyo M, and Inoue A: Osteosarcoma cell apoptosis induced by selenium. J Orthop Res 19, 809–814, 2001.
   PubMed Web of Science ®Google Scholar
• Milde D, Altamannova K, Vyslouzil K, and Stuzka V: Trace element levels in blood serum and colon tissue in colorectal cancer. Chem Pap 59, 157–160, 2005.
   Web of Science ®Google Scholar
• Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, et al.: Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166, 2034–2038, 2001.
   PubMed Web of Science ®Google Scholar
• Yadav SP, Gera A, Singh I, and Chanda R: Serum selenium levels in patients with head and neck cancer. J Otolaryngol 31, 216–219, 2002.
   PubMedGoogle Scholar
• Das A, Desai D, Pittman B, Amin S, and El-Bayoumy K: Comparison of the chemopreventive efficacies of 1,4-phenylenebis (methylene) selenocyanate and selenium enriched yeast on 4-(methylnitrosamino)-l-(3-pyridy1)-1-butanone induced lung tumorigenesis in A/J mouse. Nutr Cancer 46, 179–185, 2003.
   PubMed Web of Science ®Google Scholar
• Sanmartín C, Plano D, Sharma AK, and Palop JA: Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy. Int J Mol Sci 13, 9649–9672, 2012.
   PubMed Web of Science ®Google Scholar
• Jackson MI and Combs GF Jr: Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 11,718–726, 2008.
   PubMed Web of Science ®Google Scholar
• MaIlan DC and Parrett NA: Evaluating the efficacy of selenium-enriched yeast and sodium selenite on tissue selenium retention and se rum glutathione peroxidase activity in grower and finisher swine. J Anim Sci 74, 2967–2974, 1996.
   PubMed Web of Science ®Google Scholar
• Kabuto M, Imai H, Yonezawa C, Neriishi K, Akiba S, et al.: Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiol Biomarkers Prev 3, 465–469, 1994.
   PubMed Web of Science ®Google Scholar
• Lener MR, Gupta S, Scott RJ, Tootsi M, Kulp M, et al.: Can selenium levels act as a marker of colorectal cancer risk? BMC Cancer 13, 214, 2013.
   PubMed Web of Science ®Google Scholar
• Zuo XL, Chen JM, Zhou X, Li XZ, and Mei GY: Levels of selenium, zinc, copper and antioxidant enzyme activity in patients with leukemia. Biol Trace Elem Res 114, 41–53, 2006.
   PubMed Web of Science ®Google Scholar
• Kellen E, Zeegers M, and Buntinx F: Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. In J Urol 13, 1180–1184, 2006.
   Web of Science ®Google Scholar
• Elango N, Samuel S, and Chinnakkannu P: Enzymatic and non-enzymatic antioxidant status in stage (III) human oral squamous cell carcinoma and treated with radical radio therapy: influence of selenium supplementation. Clin Chim Acta 373, 92–98, 2006.
   PubMed Web of Science ®Google Scholar
• Charalabopoulos K, Kotsalos A, Karkabounas S, Vezyraki P, Kalfakakou V, et al.: Low selenium levels in serum and increased concentration in neoplastic tissues in patients with colorectal cancer: Correlation with serum carcinoembryonic antigen. Scand J Gastroenterol 41, 359–360, 2006.
   PubMed Web of Science ®Google Scholar
• Charalabopoulos K, Kotsalos A, Batistatou A, Charalabopoulos A, Vezyraki P, et al.: Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA. Br J Cancer 95, 674–676, 2006.
   PubMed Web of Science ®Google Scholar
• El-Bayoumy K, Upadhyaya PU, Chae YH, Sohn OS, Rao CV, et al.: Chemoprevention of cancer by Organoselenium compound. J Cell Biochem Suppl 22, 92–100, 1995.
   PubMedGoogle Scholar
• Ip C, Hayes C, Budnick RM, and Ganther HE: Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51, 595–600, 1991.
   PubMed Web of Science ®Google Scholar
• Ip C, el-Bayoumy K, Upadhyaya PU, Ganther HE, Vadhanavikit S, et al.: Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. Carcinogenesis 15, 187–192, 1994.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al.: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39–51, 2009.
   PubMed Web of Science ®Google Scholar
• Jung U, Zheng X, Yoon SO, and Chung AS: Se-Methylselenocysteine induces apoptosis mediated by reactive oxygen species in HL-60 cells. Free Radical Bio Med 31, 479–489, 2001.
   PubMed Web of Science ®Google Scholar
• Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, and Pagano M: Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15, 2612–2624, 1995.
   PubMed Web of Science ®Google Scholar
• Rayman MP: Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64, 527–542, 2005.
   PubMed Web of Science ®Google Scholar
• Wong WW and Puthalakath H: Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life 60, 390–397, 2008.
   PubMed Web of Science ®Google Scholar
• Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6, 1075–1085, 2006.
   PubMed Web of Science ®Google Scholar
• Shimomura Y, Baba R, Watanabe A, Horikoshi Y, Asami K, et al.: Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 57, 461–466, 2011.
   PubMed Web of Science ®Google Scholar